Welcome to the investors section of ADOCIA
ADOCIA is a biotechnology company specialized in the development of best-in-class medicines with already approved therapeutic proteins.
Release of 2012 Reference Document (French only)
Q1 2013 revenues
Liquidity agreement (French only)
2012 Annual Results
ADOCIA reports a revenue multiplied by 2.5 with a strong cash position for 2012
Adocia announces its financial calendar for 2013 as well as its participation to upcoming investor conferences
Adocia announces the strong growth of its turnover
Large & Midcap Event - 24-25 September 2012, Paris
SFAF meeting - Half year 2012 results. At 14:30, NYSE EURONEXT, room Auditorium - 3 rue Cambon - 75001 Paris
Financial results and business report for the first half of 2012
Additional contribution to Liquidity Agreement with Dexia Securities France (French only)
ADOCIA maintains its dynamic growth: revenue of 1st quarter 2012
2011 annual financial results - 2011: a key milestone in ADOCIA's development
ADOCIA increases the size of its Initial Public Offering to E27.4 million through the partial...
Liquidity agreement with Dexia Securities France (French only)
ADOCIA reports strong growth in operating income in 2011
ADOCIA carries out, with much success, the first IPO of the year...
ADOCIA launches its IPO on the NYSE Euronext regulated market in Paris
ADOCIA announces the registration of its Document de base (French only)